Home » Antigenics Announces Expansion of Phase II Trial in Glioma
Antigenics Announces Expansion of Phase II Trial in Glioma
Antigenics, Inc. Monday announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage vaccine; vitespen), Antigenics’ personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.
TheStreet
TheStreet
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May